Last updated on August 2019

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive HIV-1 and Hepatitis B Co-Infected Adults

Brief description of study

The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV and hepatitis B virus (HBV) treatment naive, HIV-1 and HBV co-infected adults.

Clinical Study Identifier: NCT03547908

Find a site near you

Start Over

Spectrum Medical Group

Phoenix, AZ United States
  Connect »

Be Well Medical Center

Berkeley, CA United States
  Connect »

Whitman-Walker Health

Washington, WA United States
  Connect »

Midway Immunology & Research

Fort Pierce, FL United States
  Connect »

AIDS Healthcare Foundation (AHF)

Miami Beach, FL United States
  Connect »

Orlando Immunology Center

Orlando, FL United States
  Connect »

University of Florida

Tampa, FL United States
  Connect »

Triple O Research Institute, P.A.

West Palm Beach, FL United States
  Connect »

Howard Brown Health Center

Chicago, IL United States
  Connect »

Henry Ford Health System

Detroit, MI United States
  Connect »

Southampton Healthcare, Inc.

Saint Louis, MO United States
  Connect »

Rosedale Infectious Diseases

Huntersville, NC United States
  Connect »

Queen Elizabeth Hospital

Kota Kinabalu, Malaysia
  Connect »

Hospital Kuala Lumpur

Kuala Lumpur, Malaysia
  Connect »

Hospital Pulau Pinang

Pulau Pinang, Malaysia
  Connect »

Sungai Buloh Hospital

Sungai Buloh, Malaysia
  Connect »

Seoul Medical Center

Seoul, Korea, Republic of
  Connect »